Opus Genetics (IRD) Other Non Operating Income (2010 - 2026)
Opus Genetics (IRD) posted quarterly Other Non Operating Income of $844000.0 for Q1 2026, up 179.47% year-over-year from $302000.0 in Q1 2025, and down 87.31% quarter-over-quarter from $6.7 million in Q4 2025.
Opus Genetics (IRD) Other Non Operating Income (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Other Non Operating Income for 12 consecutive years, with $844000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 179.47% year-over-year to $844000.0; the TTM figure through Mar 2026 stood at -$1.1 million (down 121.18% YoY), while the FY2025 annual figure was $848000.0, down 81.03% from the prior year.
- Other Non Operating Income slipped to $844000.0 in Q1 2026 per IRD's latest filing, from $6.7 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $6.7 million in Q4 2025 and bottomed at -$9.5 million in Q3 2025.
- Historically, Other Non Operating Income has averaged $344923.1 across 5 years, with a median of $428000.0 in 2023.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 23426.32% — and 2025, when it tumbled 2072.05%.
- Opus Genetics' Other Non Operating Income stood at -$15000.0 in 2022, then surged by 226.67% to $19000.0 in 2023, then surged by 23426.32% to $4.5 million in 2024, then jumped by 48.79% to $6.7 million in 2025, then slumped by 87.31% to $844000.0 in 2026.
- Business Quant data shows IRD's Other Non Operating Income at $844000.0 in Q1 2026, $6.7 million in Q4 2025, and -$9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Mn |
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | 6.65 Mn |
| Sep 30, 2025 | -9.53 Mn |
| Jun 30, 2025 | 917,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 4.47 Mn |
| Sep 30, 2024 | 483,000.00 |
| Mar 31, 2024 | 602,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | -707,000.00 |
| Jun 30, 2023 | 428,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Jun 30, 2022 | 15,000.00 |
| Dec 31, 2021 | -33.83 Mn |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | -33.83 Mn |
| Dec 31, 2020 | -1.50 Mn |
| Jun 30, 2020 | -919,000.00 |
| Mar 31, 2020 | 3,000.00 |